| http://www.w3.org/ns/prov#value | - It is because there has been imbalance in this view that diseases like TB, with high mortality but low profitability, are neglected by the current system of pharmaceutical research, says Dr Samir K Brahmachari, director-general, CSIR. As virtually no new TB drugs have been developed since the 1960s, the OSDD's model in particular holds great promise for the scientific community by stimulating th
|
